Literature DB >> 21733489

An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method.

Ronald J Gurrera1, Stanley N Caroff, Abigail Cohen, Brendan T Carroll, Francis DeRoos, Andrew Francis, Steven Frucht, Sanjay Gupta, James L Levenson, Ahsan Mahmood, Stephan C Mann, Michael A Policastro, Patricia I Rosebush, Henry Rosenberg, Perminder S Sachdev, Julian N Trollor, Varadaraj R Velamoor, Charles B Watson, Jayne R Wilkinson.   

Abstract

OBJECTIVE: The lack of generally accepted diagnostic criteria for neuroleptic malignant syndrome (NMS) impedes research and clinical management of patients receiving antipsychotic medications. The purpose of this study was to develop NMS diagnostic criteria reflecting a broad consensus among clinical knowledge experts, represented by an international multispecialty physician panel. PARTICIPANTS: Eleven psychiatrists, 2 neurologists, 2 anesthesiologists, and 2 emergency medicine specialists participated in a formal Delphi consensus procedure. EVIDENCE: A core bibliography consisting of 12 prominent, current reviews of the NMS literature was identified by an objective, comprehensive electronic search strategy. Each panel member was given a copy of these references and asked to examine them before commencing the survey process. CONSENSUS PROCESS: After reviewing the core bibliography, panel members were asked to list any clinical signs or symptoms or diagnostic studies that they believed, on the basis of their knowledge and clinical experience, were useful in making a diagnosis of NMS. In subsequent survey rounds, panel members assigned priority points to these items, and items that failed to receive a minimum priority score were eliminated from the next round. Information about individual panel member responses was fed back to the group anonymously in the form of the group median or mean and the number of members who had ranked or scored each survey item. The a priori consensus endpoint was defined operationally as a change of 10% or less in the mean priority score for any individual item, and an average absolute value change of 5% or less across all items, between consecutive rounds. The survey was conducted from January 2009 through September 2009.
RESULTS: Consensus was reached on the fifth round regarding the following criteria: recent dopamine antagonist exposure, or dopamine agonist withdrawal; hyperthermia; rigidity; mental status alteration; creatine kinase elevation; sympathetic nervous system lability; tachycardia plus tachypnea; and a negative work-up for other causes. The panel also reached a consensus on the relative importance of these criteria and on the following critical values for quantitative criteria: hyperthermia, > 100.4°F or > 38.0°C on at least 2 occasions; creatine kinase elevation, at least 4 times the upper limit of normal; blood pressure elevation, ≥ 25% above baseline; blood pressure fluctuation, ≥ 20 mm Hg (diastolic) or ≥ 25 mm Hg (systolic) change within 24 hours; tachycardia, ≥ 25% above baseline; and tachypnea, ≥ 50% above baseline.
CONCLUSIONS: These diagnostic criteria significantly advance the field because they represent the consensus of an international multispecialty expert panel, include critical values, provide guidance regarding the relative importance of individual elements, and are less influenced by particular theoretical biases than most previously published criteria. They require validation before being applied in clinical settings. © Copyright 2011 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21733489     DOI: 10.4088/JCP.10m06438

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  35 in total

1.  Hydrocephalus-induced neuroleptic malignant-like syndrome with reduced dopamine transporters.

Authors:  Daniel Jussen; Christian Sprung; Ralph Buchert; Johann Sebastian Braun
Journal:  J Neurol       Date:  2013-07-09       Impact factor: 4.849

2.  Early detection of an atypical presentation of neuroleptic malignant syndrome: A case report.

Authors:  P Brittany Vickery; Lindsy Meadowcraft; Stephen B Vickery
Journal:  Ment Health Clin       Date:  2018-03-23

Review 3.  [Malignant hyperthermia syndrome in the intensive care unit : Differential diagnosis and acute measures].

Authors:  W Grander
Journal:  Med Klin Intensivmed Notfmed       Date:  2016-06-07       Impact factor: 0.840

4.  Neuroleptic Malignant Syndrome Associated with Lithium Toxicity.

Authors:  Vaibhav Patil; Rishab Gupta; Rohit Verma; Yatan Pal Singh Balhara
Journal:  Oman Med J       Date:  2016-07

Review 5.  Treatment of movement disorder emergencies.

Authors:  Steven J Frucht
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

Review 6.  Neuroleptic malignant syndrome or catatonia? Trying to solve the catatonic dilemma.

Authors:  Fabian U Lang; Silke Lang; Thomas Becker; Markus Jäger
Journal:  Psychopharmacology (Berl)       Date:  2014-11-20       Impact factor: 4.530

Review 7.  [Neuroleptic malignant syndrome].

Authors:  R Knorr; J Schöllkopf; E Haen
Journal:  Nervenarzt       Date:  2018-03       Impact factor: 1.214

8.  An Approach to the Pharmacotherapy of Neuroleptic Malignant Syndrome.

Authors:  Roland van Rensburg; Eric H Decloedt
Journal:  Psychopharmacol Bull       Date:  2019-02-15

9.  Atypical Neuroleptic Malignant Syndrome Induced by Low Dose Quetiapine in a Patient Treated with Donepezil.

Authors:  Elçin Özçelik Eroğlu; M İrem Yildiz; M Kâzım Yazici
Journal:  Noro Psikiyatr Ars       Date:  2021-06-03       Impact factor: 1.339

10.  Case reports of neuroleptic malignant syndrome in context of quetiapine use.

Authors:  Mark B Detweiler; Kelly Sullivan; Taral R Sharma; Kye Y Kim; Jonna G Detweiler
Journal:  Psychiatr Q       Date:  2013-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.